PPARA and metabolic dysfunction-associated steatotic liver disease: Deducing from these studies, β-cryptoxanthin, a provitamin A, may act as an RXR ligand by metabolic conversion to retinoids in vivo via BCMO1, contributing to the improvement of NAFLD pathology through a PPAR-mediated mechanism of action involved in improving insulin resistance.